Iozomic Acid is triiodobenzoic acid derivative patented by Pharmacia Aktiebolag as X-ray contrast agent for Coronary Angiography.

Iolixanic Acid is triiodophenoxyalkoxyalkanoic acid derivative patented by Bracco Industria Chimica S.p.A. as diagnostic agent for cholecystography.

Ioseric Acid is triiodoisophthalamic acid derivative patented by Schering A.-G. as x-ray contrast media

Iotetric Acid is triiodobenzoic acid derivative with potential application as neutrophil imaging in diagnosis of cystic fibrosis.

Persilic acid is a virucide, hemostatic, capillary protective agent. 0.1% aqueous solution of K salt is used as a fluorescent acid-base indicator.

Cinnamic acid is an odorless white crystalline acid that has only been recently studied for its potential in cancer prevention. Cinnamic acid and its derivatives are the major group of phenolic acids with ubiquitous distribution in fruits and vegetables. Preclinical data support the beneficial effects of Cinnamic acid, including antioxidant, anti-inflammatory, and anti-cancer activities. A more recent botanical review noted that cinnamic acid may help pre-diabetic and diabetic patients. When infected mice were fed food loaded with cinnamic acid, researchers saw that their insulin levels were better managed. Another study which used mice models saw that cinnamic acid improved glucose tolerance by promoting insulin secretion.

Aceburic acid is the acetyl ester of gamma-hydroxybutyrate (GHB), it has analgesic effects as a prodrug to GHB. GHB is used medically as an anesthetic as well as a treatment for several neurologically affecting diseases.

Semagacestat (LY-450139) was a gamma secretase inhibitor being developed as a treatment for Alzheimer's disease by Eli Lilly. It was hoped that the drug would help to delay the onset of severe Alzheimer's disease, and thereby help preserve cognitive and executive functioning and in turn improve patient quality of life. Semagacestat (LY-450139) is designed to inhibit gamma secretase, an enzyme that is involved in the cleavage of APP to beta-amyloid. By decreasing production of beta-amyloid, it is hoped that gamma secretase inhibitors will exert a disease-modifying effect in Alzheimer's disease and thus slow or halt the destruction of nerve cells – the final stage in the amyloid cascade hypothesis. In March 2008 semagacestat (LY-450139) advanced to Phase III development, where it was evaluated in the IDENTITY (Interrupting Alzheimer's Dementia by EvaluatiNg Treatment of AmyloId PaThologY) trial, the first Phase III trial for this new anti-dementia drug. In August 2010, Eli Lilly announced its decision to halt the development of Semagacestat. The decision was taken after analysing the preliminary results of the second Phase III clinical trial of the drug, which indicated that semagacestat failed to slow disease progression. The drug, in fact, worsened cognition and the ability to perform day-to-day activities.